Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

363 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study.
Smith BD, Brümmendorf TH, Roboz GJ, Gambacorti-Passerini C, Charbonnier A, Viqueira A, Leip E, Purcell S, Goldman EH, Giles F, Ernst T, Hochhaus A, Rosti G. Smith BD, et al. Among authors: gambacorti passerini c. Leuk Res. 2024 Apr;139:107481. doi: 10.1016/j.leukres.2024.107481. Epub 2024 Mar 11. Leuk Res. 2024. PMID: 38484432 Clinical Trial.
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study.
Cortes JE, Lipton JH, Kota V, Castagnetti F, Assouline S, Brümmendorf TH, Leip E, Viqueira A, Gambacorti-Passerini C. Cortes JE, et al. Haematologica. 2023 Dec 1;108(12):3454-3459. doi: 10.3324/haematol.2022.281944. Haematologica. 2023. PMID: 37439348 Free PMC article. Clinical Trial. No abstract available.
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Jabbour E, Kantarjian HM, Aldoss I, Montesinos P, Leonard JT, Gómez-Almaguer D, Baer MR, Gambacorti-Passerini C, McCloskey J, Minami Y, Papayannidis C, Rocha V, Rousselot P, Vachhani P, Wang ES, Wang B, Hennessy M, Vorog A, Patel N, Yeh T, Ribera JM. Jabbour E, et al. Among authors: gambacorti passerini c. JAMA. 2024 May 9:e244783. doi: 10.1001/jama.2024.4783. Online ahead of print. JAMA. 2024. PMID: 38722621
Communicating the diagnosis of a hematological neoplastic disease to patients' minor children: a multicenter prospective study.
Manghisi B, Borin L, Monaco MR, Sacco GGA, Antolini L, Mantegazza R, Barichello M, Mazza U, Zappasodi P, Onida F, Arcaini L, Cairoli R, Gambacorti Passerini C. Manghisi B, et al. Among authors: gambacorti passerini c. Oncologist. 2024 May 22:oyae104. doi: 10.1093/oncolo/oyae104. Online ahead of print. Oncologist. 2024. PMID: 38775839 Free article.
BCR::ABL1 digital PCR for treatment-free remission prediction in chronic myeloid leukemia patients: An individual participant data meta-analysis.
Kockerols C, Valk PJM, Dulucq S, Nicolini FE, Mahon FX, Atallah E, Mauro MJ, Radich JP, Bernardi S, Russo D, Farina M, Mori S, Gambacorti-Passerini C, Civettini I, Lu L, Yeung D, Branford S, Colafigli G, Breccia M, Hogenbirk P, van Rosmalen J, Cornelissen JJ, Westerweel PE. Kockerols C, et al. Among authors: gambacorti passerini c. Am J Hematol. 2024 May 20. doi: 10.1002/ajh.27359. Online ahead of print. Am J Hematol. 2024. PMID: 38769689 No abstract available.
Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1.
Fontana D, Malighetti F, Villa M, Zambon A, Gambacorti-Passerini C, Mologni L. Fontana D, et al. Among authors: gambacorti passerini c. Leukemia. 2024 May 15. doi: 10.1038/s41375-024-02282-y. Online ahead of print. Leukemia. 2024. PMID: 38750137 No abstract available.
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape.
Fontana D, Zambrotta GPM, Scannella A, Piazza R, Gambacorti-Passerini C. Fontana D, et al. Among authors: gambacorti passerini c. Ann Hematol. 2024 May;103(5):1561-1568. doi: 10.1007/s00277-024-05649-4. Epub 2024 Feb 7. Ann Hematol. 2024. PMID: 38321229 Free PMC article.
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients.
Zappaterra A, Civettini I, Cafro AM, Pezzetti L, Pierini S, Anghilieri M, Bellio L, Bertazzoni P, Grillo G, Minga P, Pioltelli ML, Ravano E, Sassone M, Viganò CV, Volpato EB, Gambacorti-Passerini C, Rossini S, Cairoli R, Crocchiolo R. Zappaterra A, et al. Among authors: gambacorti passerini c. Blood Transfus. 2024 Jan 24. doi: 10.2450/BloodTransfus.667. Online ahead of print. Blood Transfus. 2024. PMID: 38315530 Free article.
Idiopathic erythrocytosis: a germline disease?
Elli EM, Mauri M, D'Aliberti D, Crespiatico I, Fontana D, Redaelli S, Pelucchi S, Spinelli S, Manghisi B, Cavalca F, Aroldi A, Ripamonti A, Ferrari S, Palamini S, Mottadelli F, Massimino L, Ramazzotti D, Cazzaniga G, Piperno A, Gambacorti-Passerini C, Piazza R. Elli EM, et al. Among authors: gambacorti passerini c. Clin Exp Med. 2024 Jan 20;24(1):11. doi: 10.1007/s10238-023-01283-y. Clin Exp Med. 2024. PMID: 38244120 Free PMC article.
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis.
Crespiatico I, Zaghi M, Mastini C, D'Aliberti D, Mauri M, Mercado CM, Fontana D, Spinelli S, Crippa V, Inzoli E, Manghisi B, Civettini I, Ramazzotti D, Sangiorgio V, Gengotti M, Brambilla V, Aroldi A, Banfi F, Barone C, Orsenigo R, Riera L, Riminucci M, Corsi A, Breccia M, Morotti A, Cilloni D, Roccaro A, Sacco A, Stagno F, Serafini M, Mottadelli F, Cazzaniga G, Pagni F, Chiarle R, Azzoni E, Sessa A, Gambacorti-Passerini C, Elli EM, Mologni L, Piazza R. Crespiatico I, et al. Among authors: gambacorti passerini c. Blood. 2024 Apr 4;143(14):1399-1413. doi: 10.1182/blood.2023021349. Blood. 2024. PMID: 38194688
363 results